IL182462A0 - Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone - Google Patents

Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone

Info

Publication number
IL182462A0
IL182462A0 IL182462A IL18246207A IL182462A0 IL 182462 A0 IL182462 A0 IL 182462A0 IL 182462 A IL182462 A IL 182462A IL 18246207 A IL18246207 A IL 18246207A IL 182462 A0 IL182462 A0 IL 182462A0
Authority
IL
Israel
Prior art keywords
days
prednisone
treatment
leukemia
graft
Prior art date
Application number
IL182462A
Other languages
English (en)
Original Assignee
Dor Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dor Biopharma Inc filed Critical Dor Biopharma Inc
Publication of IL182462A0 publication Critical patent/IL182462A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL182462A 2004-12-30 2007-04-11 Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone IL182462A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64017804P 2004-12-30 2004-12-30
PCT/US2005/047666 WO2006072093A2 (en) 2004-12-30 2005-12-30 Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone

Publications (1)

Publication Number Publication Date
IL182462A0 true IL182462A0 (en) 2008-04-13

Family

ID=36615583

Family Applications (1)

Application Number Title Priority Date Filing Date
IL182462A IL182462A0 (en) 2004-12-30 2007-04-11 Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone

Country Status (13)

Country Link
US (1) US20060252735A1 (enExample)
EP (1) EP1830857B1 (enExample)
JP (1) JP2008526773A (enExample)
KR (1) KR20070089701A (enExample)
CN (2) CN102218070A (enExample)
AT (1) ATE481102T1 (enExample)
AU (1) AU2005321826B2 (enExample)
CA (1) CA2583244A1 (enExample)
DE (1) DE602005023655D1 (enExample)
DK (1) DK1830857T3 (enExample)
IL (1) IL182462A0 (enExample)
NZ (1) NZ554326A (enExample)
WO (1) WO2006072093A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143328A1 (en) * 2001-08-13 2009-06-04 Mcdonald George Method of Treating Cancer by Administration of Topical Active Corticosteroids
AU2009333538B2 (en) * 2008-12-08 2014-09-11 Soligenix, Inc. Topically active steroids for use in radiation and chemotherapeutics injury
US20170209447A1 (en) * 2014-08-07 2017-07-27 Nitor Therapeutics Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant
CN106236736A (zh) * 2016-09-26 2016-12-21 安徽省逸欣铭医药科技有限公司 二丙酸倍氯米松肠溶缓释片及其制备方法
KR20220123004A (ko) * 2019-12-09 2022-09-05 신닥스 파마슈티컬스, 인크. 만성 이식편 대 숙주 질환의 치료를 위한 항체

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US5747474A (en) * 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
US6096731A (en) * 1998-06-24 2000-08-01 Institute For Drug Research, Inc. Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation
US20020086857A1 (en) * 2000-09-15 2002-07-04 Mcdonald George B. Method of long-term treatment of graft-versus-host disease using topical active corticosterioids
IL157921A0 (en) * 2001-03-15 2004-03-28 Enteron Pharmaceuticals Inc Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
US20030032631A1 (en) * 2001-08-13 2003-02-13 Mcdonald George B. Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteriods
JP4014912B2 (ja) * 2001-09-28 2007-11-28 株式会社ルネサステクノロジ 半導体装置

Also Published As

Publication number Publication date
CA2583244A1 (en) 2006-07-06
JP2008526773A (ja) 2008-07-24
EP1830857B1 (en) 2010-09-15
AU2005321826B2 (en) 2012-03-15
DK1830857T3 (da) 2011-02-07
NZ554326A (en) 2010-10-29
CN102218070A (zh) 2011-10-19
WO2006072093A3 (en) 2007-03-22
EP1830857A4 (en) 2008-02-27
US20060252735A1 (en) 2006-11-09
WO2006072093A2 (en) 2006-07-06
CN101060848A (zh) 2007-10-24
AU2005321826A1 (en) 2006-07-06
EP1830857A2 (en) 2007-09-12
ATE481102T1 (de) 2010-10-15
CN101060848B (zh) 2011-06-22
DE602005023655D1 (de) 2010-10-28
KR20070089701A (ko) 2007-08-31

Similar Documents

Publication Publication Date Title
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
NZ606825A (en) Methods and compositions for treating complement-associated disorders
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
RU2012106620A (ru) Комбинации и способы введения терапевтических средств и комбинированной терапии
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
IL182462A0 (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
JP2016509050A5 (enExample)
NO20080244L (no) Doseringsstyring for prasugrel
WO2006047593A3 (en) Method of potentiating inflammatory and immune modulation for cell and drug therapy
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
JP2017508737A5 (enExample)
MY166524A (en) Therapeutic substance, pharmaceutical composition, helicobacter pylori growth inhibitor and method for conducting anti-helicobacter therapy
MX2022016410A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos.
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
MY148085A (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
Boer et al. Four‐day quadruple therapy as a routine treatment for Helicobacter pylori infection
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
WO2008143014A1 (ja) がん治療剤
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
MX2022012519A (es) Endoxifeno para el tratamiento del trastorno bipolar i.
CN104324018A (zh) 广藿香醇在制备男性性功能障碍药物或保健品中的应用
WO2023225630A3 (en) FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER
CN108778310A (zh) 造血干细胞移植患者的处理
Starr Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation.